4.3 Review

Novel RNA interference-based therapies for sepsis

期刊

EXPERT OPINION ON BIOLOGICAL THERAPY
卷 14, 期 4, 页码 419-435

出版社

TAYLOR & FRANCIS LTD
DOI: 10.1517/14712598.2014.875524

关键词

chemokines; compensatory anti-inflammatory response syndrome; cytokines; delivery; microRNA; nanoparticle; RNA interference; sepsis; small interfering RNA; systemic inflammatory response syndrome

资金

  1. Alnylam Pharmaceuticals.

向作者/读者索取更多资源

Introduction: Sepsis is an extremely fast-paced disease, initiated by an infection that can progress to multiple organ dysfunction and death. The complexity associated with sepsis makes the therapies difficult to develop. Moreover, the 'one-fits-all' kind of therapy is far from being realistic. Areas covered: This review provides a conspectus of the current results of sepsis therapies and their benefits, focusing on the development of small interfering RNA (siRNA) therapeutics for targeting immune cells and sepsis pathways. Expert opinion: The question, 'When will an effective therapy for sepsis be available for patients?' remains unanswered. New RNA interference-mediated therapies are emerging as novel approaches for the treatment of sepsis by downregulating key inflammatory cytokine expression. Strategies that exploit multimodal gene silencing using siRNA and targeted delivery systems are discussed in this review. Some of these strategies have shown positive results in preclinical model of sepsis.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据